CRUK Cambridge Centre

  • Breakthrough in understanding the complexity of ovarian cancer
  • Breast cancer DNA ‘barcoding’ programme to be rolled out
  • Public event 28 September: Experimental Medicine Demystified
  • Shankar Balasubramanian and David Klenerman awarded Royal Medal
  • Making sense of cancer’s ‘big data’ to revolutionise patient care
  • How microchips could help detect prostate cancer

The CRUK Cambridge Centre is a dynamic collaboration of researchers, clinicians, and the pharmaceutical and biotech industries based in the Cambridge area. We combine world-class science and technology with excellent patient care to pioneer new ways to prevent, detect and treat cancer.

By working together across different disciplines, we are breaking down the barriers between the laboratory and the clinic, enabling patients to benefit from the latest innovations in cancer science.

Patient care and clinical research
We offer a leading cancer care specialist service at Addenbrooke’s Hospital. We are committed to translating our clinical research to improve patient outcomes by recruiting the highest proportion of patients onto clinical trials in the UK.
Over 140 research groups work together across traditional academic, commercial and clinical boundaries. We connect cutting-edge science and technology from different disciplines to shed new light on preventing and controlling cancer.
Education and training
We educate and train the next generation of cancer scientists and clinicians. Working with the University of Cambridge we provide a stimulating learning environment for undergraduates, graduates, and postdoctoral researchers.

Subscribe to Centre News Latest news and events from CRUK Cambridge Centre

Dr James Brenton (left) and Dr Geoff Macintyre, CRUK Cambridge Institute
Breakthrough study sheds light on understanding the complexity of genetic mutations in ovarian cancer.
New study reveals that it is possible to identify people at high risk of developing Acute Myeloid Leukaemia (AML) years before they became ill.
Breast screening based on women’s risk level would reduce overdiagnosis and be more cost effective say researchers from UCL and Cambridge.